ERBB2 and breast carcinoma: Importantly, MED1 knockdown significantly sensitized otherwise resistant HER2-overexpressing human breast cancer cells to anti-estrogen treatments, such as tamoxifen and fulvestrant (Cui et al., 2012; Zhang et al., 2013).